As postpartum depression shadows the joy of many new mothers, Zuranolone emerges as a promising oral alternative, addressing the constraints of the current intravenous treatment.
Postpartum depression (PPD) occurs in about 6.5% to 20% of women[1]. While the birth of a child is traditionally associated with happiness and . . .
Sign Up or Log In as a healthcare professional to read the full article.